Crohn's disease
J Torres, S Mehandru, JF Colombel, L Peyrin-Biroulet - The Lancet, 2017 - thelancet.com
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with
increasing incidence worldwide. Crohn's disease might result from a complex interplay …
increasing incidence worldwide. Crohn's disease might result from a complex interplay …
Ulcerative colitis and Crohn's disease have similar burden and goals for treatment
C Le Berre, AN Ananthakrishnan, S Danese… - Clinical …, 2020 - Elsevier
It is unclear whether ulcerative colitis (UC) is a progressive disease similar to Crohn's
disease (CD). Patients with UC often are undertreated because of the possibility of curative …
disease (CD). Patients with UC often are undertreated because of the possibility of curative …
STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD …
D Turner, A Ricciuto, A Lewis, F D'amico, J Dhaliwal… - Gastroenterology, 2021 - Elsevier
Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo …
BG Feagan, WJ Sandborn, G D'Haens, J Panés… - The Lancet, 2017 - thelancet.com
Background The interleukin-23 pathway is implicated genetically and biologically in the
pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of …
pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of …
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial
CY Ponsioen, EJ de Groof, EJ Eshuis… - The lancet …, 2017 - thelancet.com
Background Treatment of patients with ileocaecal Crohn's disease who have not responded
to conventional therapy is commonly scaled up to biological agents, but surgery can also …
to conventional therapy is commonly scaled up to biological agents, but surgery can also …
The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn's disease: results from the US VICTORY Consortium
The Real-World Effectiveness and Safety of Vedolizumab for M... : Official journal of the American
College of Gastroenterology | ACG The Real-World Effectiveness and Safety of Vedolizumab for …
College of Gastroenterology | ACG The Real-World Effectiveness and Safety of Vedolizumab for …
Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease
Background & Aims Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23,
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …
Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease
BE Sands, L Peyrin-Biroulet, J Kierkus, PDR Higgins… - Gastroenterology, 2022 - Elsevier
Background Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19
with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and …
with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and …
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
BG Feagan, J Panés, M Ferrante, A Kaser… - The Lancet …, 2018 - thelancet.com
Background Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in
achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction …
achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction …
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
Background Butyrate has shown anti‐inflammatory and regenerative properties, providing
symptomatic relief when orally supplemented in patients suffering from various colonic …
symptomatic relief when orally supplemented in patients suffering from various colonic …